NYSE:IQVLife Sciences
How IQVIA’s Medera Cardiac Gene Therapy Alliance and Raised 2026 Outlook Will Impact IQV (IQV) Investors
In late July and early August 2026, IQVIA Inc. and Medera Inc. announced a collaboration to advance cardiac gene therapies and human-based drug discovery, alongside IQVIA reporting second-quarter results, updating buyback activity, and raising full-year 2026 revenue guidance to US$17.28–US$17.48 billion with a third-quarter outlook of US$4.32–US$4.39 billion.
A key aspect of this news is how IQVIA’s trial execution, regulatory support, and commercialization infrastructure will be integrated...